Ovarian cancer remains one of the deadliest gynecologic malignancies, primarily due to the propensity of tumor cells to metastasize throughout the peritoneal cavity and develop resistance against conventional chemotherapeutic regimens. Despite administration of neoadjuvant chemotherapy (NACT), a significant subset of patients experiences relapse attributed to the survival and expansion of cancer stem-like cells embedded within the peritoneal microenvironment. These cancer stem cells (CSCs) possess self-renewal capabilities and exhibit heightened resistance to cytotoxic agents, necessitating a deeper understanding of the molecular drivers that sustain their stemness.

Employing sophisticated proteomic strategies including tandem mass tag (TMT) labeling combined with tissue microarray analysis, the research team meticulously characterized residual tumor tissues post-chemotherapy to identify key protein alterations associated with therapy resistance. Their findings pinpoint YWHAB as a critical regulatory factor whose down-regulation correlates with enhanced nuclear accumulation of YAP, a potent oncogenic transcriptional effector implicated in multiple tumor types. The diminished YWHAB expression disrupts its binding with YAP, fostering YAP’s translocation into the nucleus where it orchestrates the activation of downstream gene networks central to proliferation, stemness, and drug resistance.

Detailed mechanistic investigations highlight that YWHAB interacts directly with the SH3 domain of YAP, sequestering it within the cytoplasm and thereby preventing its nuclear function. The attenuation of YWHAB expression abrogates this cytoplasmic retention mechanism, resulting in increased YAP-TEAD transcriptional complex formation that triggers expression of a panel of genes facilitating tumor cell plasticity and survival in hostile conditions, such as those induced by chemotherapy. This finding underscores the importance of the YWHAB-YAP axis in maintaining cellular homeostasis and suppressing malignant progression.

Functionally, in vitro models demonstrate that silencing YWHAB significantly increases the formation and size of ovarian cancer spheroids—three-dimensional structures that serve as in vitro surrogates for tumor stemness and metastatic potential. Furthermore, YWHAB-deficient cells exhibit pronounced resistance to cisplatin, one of the frontline chemotherapeutic agents for ovarian cancer, strengthening the link between YWHAB regulation and chemoresistance. These phenotypic changes offer compelling evidence that YWHAB plays an indispensable role in modulating CSC properties in OCPM.

Extending their analyses to in vivo systems, the researchers employed murine xenograft models to validate the tumorigenic impact of YWHAB deficiency. Mice implanted with YWHAB knockdown ovarian cancer cells developed larger tumors with increased metastatic dissemination compared to controls, confirming the pro-oncogenic consequences of disrupting YWHAB-mediated YAP retention. This in vivo validation substantiates the clinical relevance of targeting the YWHAB-YAP molecular interaction as a promising strategy to stifle ovarian cancer progression and metastasis.

Concurrently, epigenetic profiling revealed alterations in the promoter region of the YWHAB gene in chemoresistant tumor cells, suggesting that epigenetic repression contributes to its diminished expression. These epigenetic modifications potentially serve as upstream regulators diminishing YWHAB availability, which in turn unleashes unchecked YAP activity. Such insights into the regulatory landscape provide novel angles for therapeutic intervention, including epigenetic reprogramming to reinstate YWHAB expression.

The study’s revelations about the YWHAB-YAP signaling nexus not only deepen the molecular understanding of ovarian cancer stemness and chemoresistance but also open new avenues for targeted therapy development. By disrupting YAP’s nuclear activity or reinforcing YWHAB function, it may be possible to curb tumor relapse and improve patient survival. Notably, the identified necessity of the SH3 domain within YAP for YWHAB binding points to potential sites for small molecule or peptide inhibitor design.

Given the high mortality rate associated with ovarian cancer peritoneal metastasis and limited efficacy of current therapeutic options, these findings offer a beacon of hope in the ongoing quest to personalize and enhance treatment paradigms. Clinical translations aimed at modulating the YWHAB-YAP axis require further investigation, yet the present study lays a foundation for such endeavors by furnishing robust experimental and translational evidence.

In conclusion, this landmark research underscores the criticality of YWHAB in maintaining cellular equilibrium by tethering YAP in the cytoplasm, thereby curbing the malignant phenotypes driven by YAP nuclear transcriptional activity. The disruption of this balance propels stemness and chemoresistance, which are formidable barriers in treating ovarian cancer metastasis. Targeting this pathway could revolutionize therapeutic strategies and yield substantial improvements in patient outcomes.

As elucidated in these comprehensive proteomic and functional assays, future research focused on developing pharmacological agents to reinforce YWHAB-mediated YAP retention or directly inhibit YAP nuclear functions holds promise. Such targeted interventions, combined with existing chemotherapy, may overcome the challenge of resistant ovarian cancer stem cells, ultimately reducing relapse rates and extending survival.

This study epitomizes the importance of dissecting cancer’s molecular underpinnings to reveal vulnerabilities that can be exploited for clinical benefit. The elucidation of YWHAB’s restraining role on YAP adds a crucial piece to the ovarian cancer puzzle and paves the way for innovative anti-cancer therapies tackling metastasis and drug resistance at their core.

Subject of Research: Ovarian cancer peritoneal metastasis, cancer stemness, chemoresistance

Article Title: Restriction of YWHAB-mediated YAP cytoplasmic retention is a novel mechanism underlying stemness maintenance and chemoresistance in ovarian cancer peritoneal metastasis

Web References: http://dx.doi.org/10.1016/j.gendis.2025.101519

References: Chang Liu, Lei Shi, Zijun Meng, Manlin Zhang, Zhiqi Zhang, Yunzhe Li, Kaiwen Du, Muyao Yang, Lin Qiu, Jing Feng, Yuchen He, Jiayun Liu, Hua Zhang, Hongbin Zhang, Tingyuan Lang, Zhuo Yang, Genes & Diseases, 2025, 101519

Image Credits: Genes & Diseases

Keywords: Ovarian cancer, peritoneal metastasis, chemoresistance, cancer stem cells, YWHAB, YAP, proteomics, neoadjuvant chemotherapy, tumor stemness, epigenetics, SH3 domain, transcriptional regulation

The reality of chemotherapy for EAC patients is particularly stark. Despite receiving one of several available chemotherapeutic agents, patients frequently lack any reliable method to ascertain the likelihood of treatment effectiveness. Responders may still face the grim possibility that their tumors will continue to progress or even metastasize, underscoring the dire need for personalized treatment solutions in this domain. To bridge this gap, researchers have embarked on developing a tailored precision oncology model that can yield timely predictions regarding individual responses to chemotherapy, representing a critical unmet medical need.

In recent endeavors to address the complexities of EAC, innovative methodologies have been pursued, notably the development of organoids derived from patient biopsies. These three-dimensional structures, effectively miniature organ replicas, replicate certain characteristics of the esophageal epithelial lining. However, these organoids often fall short of capturing the complete tumor microenvironment (TME), which encompasses essential elements such as stromal fibroblasts and extracellular matrix components. The inadequacy of standard organoid models to accurately mimic the chemotherapeutic responses characteristic of actual tumors has been a significant barrier to advancing treatment options.

A promising new avenue has emerged from a collaboration led by renowned experts Donald Ingber, M.D., Ph.D., and Lorenzo Ferri, M.D. Their groundbreaking work focuses on integrating human Organ Chip microfluidic technology, initially pioneered at the Wyss Institute, with patient-specific EAC organoids and corresponding stromal elements from the same biopsies. By co-culturing these components, researchers have succeeded in creating Cancer Chip models that closely represent the complexities of individual TME. This innovative approach elucidates new levels of physiologic relevance in vitro, enhancing the accuracy with which patient-specific responses to NACT can be predicted.

A remarkable aspect of this approach lies in its efficiency; researchers can generate results within a mere 12 days, enabling rapid stratification of patients into responders and non-responders. This timely output is vital for incorporating clinical decisions regarding chemotherapy agents, particularly for those patients exhibiting chemoresistance. The anticipation surrounding this data-driven approach has been heightened given its potential to reshape treatment paradigms and foster collaborations between clinical oncology and laboratory research.

Returning to the foundational principles of Engineering Biology, Ingber and Ferri’s teams harnessed a wealth of experience from prior studies, utilizing their successes with Barrett’s esophagus models. Barrett’s esophagus serves as a critical precursor to EAC and highlights the transformative impact of evironmental factors, such as acid exposure, on cellular behavior and tumorigenesis. In the new study, researchers transitioned from an examination of precancerous stages to directly modeling the malignancy, emphasizing the importance of the stromal contributions to cancer progression and TME dynamics.

Patient-derived EAC organoids were meticulously engineered from endoscopic biopsies of individuals at an early diagnosis stage, ensuring a level of specificity and relevance. Researchers adeptly isolated various cellular components from these biopsies, integrating tumor-associated fibroblasts into the microfluidic setting to foster intercellular communications akin to those observed in natural tumors. These newly developed systems epitomize an unprecedented level of biomimicry that holds the promise of yielding rich insights into the interactions governing cancer growth and treatment responses.

The intricate engineering of these chips allowed for dynamic interactions between cancer cell lines and the stroma, which contains immune components and vasculature. This carefully orchestrated mimicry effectively mirrored patient tumor biology. Notably, the experimental setup enabled researchers to introduce low-dose, patient-specific chemotherapy within a nutritionally rich environment that simulates the physiological conditions prevalent in vivo. By maintaining the complexities of fluid flows and nutrient gradients, these chips delivered a scientifically rigorous platform for testing and analyzing treatment effectiveness.

In preclinical trials targeting a cohort of eight patients, the EAC Chips delivered extraordinary outcomes, accurately predicting responses within the critical 12-day window. Half of the chips demonstrated sensitivity to chemotherapy, evidenced by notable cell death, while the remaining cells exhibited resilience against the treatment. These experimental results demonstrated a striking correlation with the patients’ actual clinical outcomes, a validation that emphasizes the translational potential of this technology.

The implications of these findings are far-reaching, suggesting not only the enhancement of current understanding regarding chemotherapy responsiveness but also the potential to inform future pharmaceutical development. This partnership between laboratory insights and clinical application cultivates an environment ripe for breakthroughs in personalized medicine across various cancer types. Biologically-relevant modeling may pave the way for revolutionizing treatments to target both tumor and stromal elements, generating a deeper understanding of the molecular signatures that determine treatment success.

As the results of this seminal study make their way into clinical practice, it is essential to recognize the promising strides taken in the realm of precision oncology. The methodologies developed via the integration of patient-specific chips significantly contribute to a broader discourse concerning personalized medicine, which is set to enhance treatment for esophageal adenocarcinoma and beyond. Researchers express optimism that these innovations will translate into new therapeutic avenues and crucial biomarkers for ongoing patient monitoring, ultimately raising the bar for cancer care.

Overall, the collaborative work led by Ingber and Ferri symbolizes a critical advancement in cancer research, showcasing how cutting-edge technologies can be harnessed to directly impact patient outcomes. The precision engineering of organ-on-chip technologies not only has implications for EAC treatment but also exemplifies a framework for rethinking therapeutic strategies across a spectrum of cancers. The continual evolution of such technologies will be paramount in developing effective strategies to tackle the complexities of cancer biology.

In summary, the research signifies a monumental leap forward in understanding and overcoming treatments for EAC, setting new standards for personalized therapeutic approaches. By fostering collaboration across clinical and technological domains, the hope for more effective cancer treatment strategies appears brighter than ever before.

Subject of Research: Esophageal adenocarcinoma Treatment
Article Title: Patient-derived esophageal adenocarcinoma organ chip: a physiologically relevant platform for functional precision oncology
News Publication Date: 23-May-2025
Web References:
References:
Image Credits: Credit: Wyss Institute at Harvard University

Keywords